Syntis Bio Secures $33 Million to Advance Oral Weight Loss Therapies

Syntis Bio raises $33 million in Series A funding to advance its oral SYNT platform, including SYNT-101 for obesity and SYNT-202 for rare disease. With additional NIH grant support, the company aims to transform weight loss and metabolic health treatment through non-invasive drug delivery.